NCT06915168Recruiting
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer
CIPN Decision Aid to Improve Neurotoxic Chemotherapy Decision Making
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This clinical trial studies how well a chemotherapy-induced peripheral neuropathy (CIPN) decision aid works in improving chemotherapy decision making among patients with breast cancer. CIPN involves numbness or tingling in the hands or feet and is a debilitating side effect of several commonly used classes of cancer drugs. CIPN symptoms are typically minor at first but can progress with continued treatment to severe symptoms that can affect long-term function, falls risk, and quality of life. Symptoms sometimes resolve after treatment but in patients who experienced CIPN, symptoms are still present 1 year post-treatment in about two-thirds of patients and 3 years post-treatment in approximately half of the patients. Previous studies indicate patients lack awareness of long-term CIPN symptoms. A decision aid that provides information about permanent CIPN, that helps patients understand their treatment priorities, and prepares them for a discussion with their medical oncologist may lead to improvements in treatment decision making, satisfaction with decision making, and ultimately increase patient's achievement of their treatment goals.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 11 Mar 2025
- Start date
- 13 Nov 2024
- Primary completion date
- Mar 2027
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Diseases
- Childhood cancers
- NCT number
- NCT06915168
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 13 Nov 2024 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to read or speak English
Who the study is looking for
- Patients with breast cancer
- Currently receiving cycle three of taxane treatment
- Approval of medical oncologist to enroll patient
- Experiencing any CIPN based on enrollment screening question, "In the last 7 days, what was the severity of your numbness or tingling in your hands or feet at its worst? None, Mild, Moderate, Severe, Very Severe. Patient is eligible if their answer is anything except "None"
- Access to a smartphone or similar device that can complete CIPN DecisionAid via Qualtrics while in the waiting room
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Of Michigan Comprehensive Cancer Center Coordinator of this site? Confirm its status | Ann Arbor | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.